In recent years, humanity has seen which health threats viral diseases can pose to life. At the same time, our bodies are equipped with a powerful network that needs to be unleashed to successfully overcome such threats. At Belyntic, we develop T-cell immunotherapies against diseases with significant unmet medical needs based on self-adjuvant peptide vaccines. We are about to start the preclinical development of our first vaccine candidate against PML, a rare but fatal neurodegenerative disease.